Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback